Sign In
Buy ALPN
$64.97
+0 (+0%)
At Close: Aug 19, 2024
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
12:02pm, Monday, 11'th Dec 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?
11:19am, Wednesday, 29'th Nov 2023
Here is how Alpine Immune Sciences, Inc. (ALPN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Alpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains?
11:17am, Monday, 30'th Oct 2023
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher
Alpine Immune Sciences, Inc. (ALPN) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:32pm, Monday, 23'rd Oct 2023
Alpine Immune Sciences, Inc. (ALPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for October 23rd
08:16am, Monday, 23'rd Oct 2023
MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
Alpine Immune Sciences: November 2023 Data Release Could Get Ball Rolling
03:31pm, Friday, 06'th Oct 2023
Preliminary clinical data from the Alpine Immune Sciences, Inc. ongoing phase 3 RUBY-3 study will be presented at the American Society of Nephrology Annual Kidney Week Meeting in November 2023. The st
Here's Why You Should Invest in Alpine (ALPN) Stock Now
09:46am, Tuesday, 19'th Sep 2023
Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
10:32am, Monday, 18'th Sep 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
Alpine Immune Sciences, Inc. (ALPN) Is a Great Choice for 'Trend' Investors, Here's Why
10:32am, Thursday, 24'th Aug 2023
Alpine Immune Sciences, Inc. (ALPN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that
Alpine Immune (ALPN) Stock Up 19% MTD, Will the Uptick Continue?
08:51am, Thursday, 22'nd Jun 2023
Alpine Immune has been riding on positive momentum surrounding its under-development drug program.
Alpine Immune Sciences, Inc. (ALPN) Soars 5.6%: Is Further Upside Left in the Stock?
02:03am, Wednesday, 21'st Jun 2023
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
04:30pm, Friday, 19'th May 2023
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseas
Alpine Immune: Rebuilding Itself From Scratch, But Long Way To Go Before Proof
07:37am, Wednesday, 29'th Mar 2023
Last year, ALPN ditched its lead program after a second patient death in a CD28 molecule, a previously notorious pathway. ALPN has started all over again, with backing from a few big pharma.
Alpine Immune Sciences, Inc. (ALPN) Q4 2022 Earnings Call Transcript
07:41pm, Thursday, 23'rd Mar 2023
Alpine Immune Sciences, Inc. (NASDAQ:ALPN ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Temre Johnson - SD, IR Mitchell Gold - Executive Chairman, CEO Stanford Peng
